Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recombinant Production of Mecasermin in E. Coli Expression System



Jafari S1 ; Babaeipour V1, 5 ; Seyedi HAE2 ; Rahaie M1 ; Mofid MR2 ; Haddad L2 ; Namvaran MM3 ; Fallah J4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Life Science Engineering, Faculty of New Science and Technologies, University of Tehran, Iran
  2. 2. Department of Biochemistry, Isfahan Pharmaceutical Research Center and Bioinformatics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran
  4. 4. Genetic Engineering Group, Biotechnology Research Center, Malek Ashtar University of Technology, Tehran, Iran
  5. 5. Biochemistry Group, Biotechnology Research Center, Malek Ashtar University of Technology, Tehran, Iran

Source: Research in Pharmaceutical Sciences Published:2014

Abstract

Human Insulin-like growth factor 1 (hIGF-1) consists of 70 amino acids in a single chain with three intermolecular disulfide bridges possessing valuable therapeutic effects. To date, numerous variants of specifically engineered hIGF-1 have been produced so as to improve hIGF-1 biological activity, stability and stronger binding to IGF-1 receptor. Mecasermin is one of the modified variants with one amino acid substitution near the N-terminal (T4I) approved for the treatment of growth failure diabetes, wound healing, amyotrophic lateral sclerosis and severe primary IGF-1 deficiency. No scientific report for recombinant production of mecasermin in Escherichia coli (E. coli) expression system has been sofar reported. In the present study, we therefore investigated the overexpression of mecasermin in two different E. coli strains in order to obtain higher yield of recombinant protein. To achieve this goal, mecasermin DNA encoding sequence was designed based on polypeptide sequence, optimized according to E. coli codon preference, and cloned in pET15b. Recombinant vector, pET15-mecasermin, transferred into two E. coli strains rigami B (DE3) and BL21 (DE3) and induced for expression in a small scale. Results revealed the E. coli Origami B (DE3) expression system was a preferable host for mecasermin production due to its high expression level being around twice as much as BL21 (DE3). Large scale mecasermin production was performed in batch culture and produced recombinant protein specifically confirmed by western blotting and mass spectroscopy. Since major part of recombinant mecasermin was expressed as inclusion body, isolation and refolding was accomplished through developed purification procedure, and finally recombinant protein was successfully purified by gel filtration chromatography.
Related Docs
1. Enhanced Production of Insulin-Like Growth Factor I Protein in Escherichia Coli by Optimization of Five Key Factors, Iranian Journal of Pharmaceutical Research (2015)
2. Design and Production of a Novel Chimeric Human Growth Hormone Superagonist Fused to Human Fc Domain, Research in Pharmaceutical Sciences (2022)
3. Efficient Process Development for High-Level Production, Purification, Formulation, and Characterization of Recombinant Mecasermin in Escherichia Coli, Biotechnology and Applied Biochemistry (2021)
4. Optimization of the Expression of Reteplase in Escherichia Coli Top10 Using Arabinose Promoter, Jundishapur Journal of Natural Pharmaceutical Products (2015)
5. Optimization of Buffer Additives for Efficient Recovery of Hgm-Csf From Inclusion Bodies Using Response Surface Methodology, Iranian Journal of Pharmaceutical Research (2020)
6. Recombinant Production, Purification and Characterization of Vessel Dilator in E. Coli, Protein Expression and Purification (2017)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Mofid (3)
Hamid Mirmohammad Sadeghi (1)